Skip to main content

A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following HSCT

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Infectious Diseases

Awarded By

Merck Sharp & Dohme

Start Date

October 10, 2018

End Date

October 31, 2023
 

Administered By

Pediatrics, Infectious Diseases

Awarded By

Merck Sharp & Dohme

Start Date

October 10, 2018

End Date

October 31, 2023